GSK, ovarian cancer and Jemperli

GSK's cancer drug combo meets main goal in ovarian cancer trial
GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial,
Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goal
Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the third quarter.
GSK's cancer drugs meet progression-free survival goal in late-stage trial
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial.
GSK's Cancer Drugs Zejula, Jemperli Met Its Primary Key Goal in Late-Stage Study
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Researchers developing ways to diagnose ovarian cancer sooner
Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms ...
News Medical on MSN5d
Global study reveals shifting trends in ovarian cancer incidence by subtype and region
Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by ...
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...
labiotech4d
Ovarian cancer: BioNTech, Curelab, OvarianVax and more bring vaccines to the clinic
A number of ovarian cancer vaccines are being evaluated including the world's first cancer prevention vaccine, which recently ...
How chemotherapy primes ovarian cancer for immune-based therapies
Researchers have discovered how chemotherapy can change tumors, making them more vulnerable to new types of treatments. These ...
Pharmabiz15h
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
News Medical on MSN10d
Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response
Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of ...
Drug developer seeks $100M for new cancer treatment
Incyclix Bio seeks $100 million to support cancer studies. The company is developing a CDK2 inhibitor called INX-315.
WDEL-FM23h
Above and beyond in the fight against cancer
New Castle County police officers, and members of Fraternal Order of Police Lodge #5, went above and beyond the call of duty ...
Anthem Blue Cross contract fight could see 22K Sloan Kettering cancer patients lose life-saving treatments
The impasse comes as health insurance companies have faced heightened scrutiny following UnitedHealthcare CEO Brian ...